[Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
[Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection]. [electronic resource]
- MMW Fortschritte der Medizin Jun 2014
- 53 p. digital
Publication Type: Comparative Study; Journal Article
1438-3276
Antiviral Agents--adverse effects
Drug Therapy, Combination
Hepacivirus--drug effects
Hepatitis C, Chronic--drug therapy
Heterocyclic Compounds, 3-Ring--adverse effects
Humans
Interferons--adverse effects
Protease Inhibitors--adverse effects
Randomized Controlled Trials as Topic
Ribavirin--adverse effects
Secondary Prevention
Simeprevir
Sofosbuvir
Sulfonamides--adverse effects
Uridine Monophosphate--adverse effects
Publication Type: Comparative Study; Journal Article
1438-3276
Antiviral Agents--adverse effects
Drug Therapy, Combination
Hepacivirus--drug effects
Hepatitis C, Chronic--drug therapy
Heterocyclic Compounds, 3-Ring--adverse effects
Humans
Interferons--adverse effects
Protease Inhibitors--adverse effects
Randomized Controlled Trials as Topic
Ribavirin--adverse effects
Secondary Prevention
Simeprevir
Sofosbuvir
Sulfonamides--adverse effects
Uridine Monophosphate--adverse effects